GlaxoSmithKline plc GSK and partner Johnson & Johnson JNJ announced that Japan's Ministry of Health, Labour and Welfare granted a marketing approval to Juluca for the maintenance treatment of HIV -1 infection.
Juluca combines two approved HIV drugs — Tivicay (50 mg) and Edurant (25 mg) — into a single, once-daily pill for the treatment of virologically suppressed HIV-1 infection.
Tivicay, a novel investigational integrase strand transfer inhibitor (INSTI), is marketed by ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer Inc. PFE. Edurant is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Janssen, J&J's pharma arm. Juluca has been developed under a partnership between ViiV Healthcare and Janssen.
Related Links:
9 Policy Catalysts For Health Care Investors To Watch Before Year's End
The Health Care Stocks With A Lot Riding On The Midterm Elections
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.